Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Tax Reform Could Lead to Spike in Biopharma M&A Activity

16h biospace
The passing of tax reform led most analysts to predict that 2018 will be a strong year for mergers and acquisitions. Data and analytics firm GlobalData followed suit. Rahael Maladwala, a healthcare analyst with the company, said in a recent report, “The tax reform includes a huge cut in the overall tax rate, down to less than 20 percent for most companies, leaving large pharmaceutical giants with an influx of excess cash. (32-0)

Genmab's (GNMSF) CEO Jan van de Winkel on Q4 2017 Results - Earnings Call Transcript

2018-02-22 seekingalpha
Good day, everyone and welcome to the Genmab Q4 Report 2017 Conference Call. Today's conference is being recorded. During this telephone conference, you may be presented with forward-looking statements that include words such as believes, anticipates, plans or expects. Actual results may differ materially, for example as a result of delayed or unsuccessful development projects. Genmab is not under any obligation to update statements regarding the future, nor to confirm such statements in relation to actual results unless this is required by law. (4-0)

Advaxis' Chances: What Can EMA Failures Tell Us About Its Future?

2018-02-19 seekingalpha
In spite of this, the company has achieved a monumental goal of submitting for marketing authorization with the EMA. (194-0)

JF's Core Biotech Buys Edition 1 Volume 3: 2 New Purchases, Plus Thoughts On Portfolio Management And Performance

2018-02-19 seekingalpha
For those new to this series, it is a reboot back by popular request where we aid readers with a longer-term focus in building a diversified biotech portfolio. (279-0)

Merger And Acquisition: What Can Investors Learn From The Seattle Genetics Buyout Of Cascadian?

2018-02-18 seekingalpha
This M&A satisfied 50% of our criteria conducive to a buyout. For one, there is pipeline synergy. (107-1)

SGEN / Seattle Genetics, Inc. AMENDMENT NO. 1 TO SC TO-T

2018-02-17 sec.gov
AMENDMENT NO. 1 TO SC TO-T     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     SCHEDULE TO (RULE 14d-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1)     CASCADIAN THERAPEUTICS, INC. (Name of Subject Company (Issuer)) VALLEY ACQUISITION SUB, INC. (Offeror) SEATTLE GENETICS, INC. (Parent of Offeror) (Names of Filing Persons)     COMMON STOCK, PAR VALUE $0.

SGEN / Seattle Genetics, Inc. AMENDMENT NO. 1 TO SC TO-T

2018-02-17 sec.gov
AMENDMENT NO. 1 TO SC TO-T     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     SCHEDULE TO (RULE 14d-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1)     CASCADIAN THERAPEUTICS, INC. (Name of Subject Company (Issuer)) VALLEY ACQUISITION SUB, INC. (Offeror) SEATTLE GENETICS, INC. (Parent of Offeror) (Names of Filing Persons)     COMMON STOCK, PAR VALUE $0.

BRIEF-Seattle Genetics Announces Expiration Of Hart-Scott-Rodino Waiting Period

2018-02-16 reuters
* SEATTLE GENETICS - ‍REQUIRED WAITING PERIOD UNDER HART-SCOTT-RODINO ACT REGARDING CO‘S PROPOSED ACQUISITION OF CASCADIAN THERAPEUTICS EXPIRED ON FEB 15, 2018​ Source text for Eikon: Further company coverage: (4-0)

Merus: This ROTY Holding Flashed A Buy Signal

2018-02-16 seekingalpha
I remind readers of clinical catalysts that could serve to push shares higher, including safety and early activity mid-year for MCLA-117 in AML. (24-0)

SGEN / Seattle Genetics, Inc. 10-K (Annual Report)

2018-02-15 sec.gov
10-K Table of Contents     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 10-K (Mark One)   ☒   ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR   ☐   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from              to                      Commission file number: 0-32405   Seattle Genetics, Inc.

SGEN / Seattle Genetics, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - 3G (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) SEATTLE GENETICS INC /WA (Name of Issuer) COMMON STOCK (Title of Class of Securities) 812578102 (CUSIP NUMBER) December 31, 2017 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1.

SGEN / Seattle Genetics, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - 3G (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) SEATTLE GENETICS INC /WA (Name of Issuer) COMMON STOCK (Title of Class of Securities) 812578102 (CUSIP NUMBER) December 31, 2017 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1.

Tracking Seth Klarman's Baupost Group Holdings - Q4 2017 Update

2018-02-14 seekingalpha
The portfolio continues to be heavily concentrated, with the top three positions accounting for one-third of the 13F portfolio. (376-11)

SGEN / Seattle Genetics, Inc. / Capital International Investors - SC 13G (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Seattle Genetics Incorporated (Name of Issuer) Common Stock (Title of Class of Securities) 812578102 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of thi

SGEN / Seattle Genetics, Inc. / Capital International Investors - SC 13G (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Seattle Genetics Incorporated (Name of Issuer) Common Stock (Title of Class of Securities) 812578102 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of thi


CUSIP: 812578102